Biocept Stock Price To Earning
Biocept fundamentals help investors to digest information that contributes to Biocept's financial success or failures. It also enables traders to predict the movement of Biocept Stock. The fundamental analysis module provides a way to measure Biocept's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biocept stock.
Biocept |
Biocept Company Price To Earning Analysis
Biocept's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Biocept Price To Earning | 5.34 X |
Most of Biocept's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biocept is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Biocept has a Price To Earning of 5.34 times. This is 79.33% lower than that of the Biotechnology sector and 79.5% lower than that of the Health Care industry. The price to earning for all United States stocks is 81.41% higher than that of the company.
Biocept Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biocept's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biocept could also be used in its relative valuation, which is a method of valuing Biocept by comparing valuation metrics of similar companies.Biocept is currently under evaluation in price to earning category among its peers.
Biocept Fundamentals
Return On Equity | -1.87 | |||
Return On Asset | -0.52 | |||
Operating Margin | (10.38) % | |||
Current Valuation | 5.92 M | |||
Shares Outstanding | 2.63 M | |||
Shares Owned By Insiders | 9.20 % | |||
Shares Owned By Institutions | 1.98 % | |||
Number Of Shares Shorted | 29.73 K | |||
Price To Earning | 5.34 X | |||
Price To Book | 0.37 X | |||
Price To Sales | 0.20 X | |||
Revenue | 25.86 M | |||
Gross Profit | (2.58 M) | |||
EBITDA | (31.98 M) | |||
Net Income | (32.09 M) | |||
Cash And Equivalents | 27.57 M | |||
Cash Per Share | 1.63 X | |||
Total Debt | 12.11 M | |||
Debt To Equity | 0.33 % | |||
Current Ratio | 3.38 X | |||
Book Value Per Share | 0.12 X | |||
Cash Flow From Operations | (13.29 M) | |||
Short Ratio | 0.05 X | |||
Earnings Per Share | (48.17) X | |||
Price To Earnings To Growth | (0.04) X | |||
Target Price | 4.0 | |||
Number Of Employees | 50 | |||
Beta | 0.6 | |||
Market Capitalization | 1.14 M | |||
Total Asset | 30.87 M | |||
Retained Earnings | (298.44 M) | |||
Working Capital | 10.84 M | |||
Current Asset | 9.64 M | |||
Current Liabilities | 3.34 M | |||
Z Score | -15.64 | |||
Net Asset | 30.87 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Biocept Stock
If you are still planning to invest in Biocept check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biocept's history and understand the potential risks before investing.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Transaction History View history of all your transactions and understand their impact on performance | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |